FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Andere Sprachen Frazier Lifesciences Acquisition Corporation

Aktien

NAMS

NL00150012L7

NAMS

Realtime-Estimate Tradegate Andere Börsenplätze 19:55:00 06.06.2024			% 5 Tage	% 1. Jan.
17,75 ^EUR	-7,65 %		+1,26 %	+72,07 %

21.05.	NewAmsterdam Pharma Company N.V. präsentiert neue klinische und präklinische Daten, die den Einfluss von Obicetrapib auf die wichtigsten Risikofaktoren für Herz-Kreislauf-Erkrankungen auf kommenden medizinischen Kongressen hervorheben	CI
16.05.	Transcript : NewAmsterdam Pharma Company N.V. - Special Call

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29.05.
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29.05.
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21.05.
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21.05.
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings	21.05.
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	09.05.
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09.05.
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02.05.
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02.05.
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09.04.
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09.04.
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01.04.
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01.04.
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01.04.
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01.04.
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	27.03.
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	25.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Frazier Lifesciences Acquisition Corporation

Aktien

NAMS

NL00150012L7

NAMS

Andere Sprachen

Filter